Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V184 in Previously Exposed Adults
NCT03807843Phase 2Completed
- Sponsor
- Themis Bioscience
- Start
- Jul 2019
- Primary completion
- May 2021
- Modality
- Live Attenuated Vaccines, Recombinant Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chikungunya (CHIKV) comparing V184 with Placebo (2 arms). Primary endpoints: Number of Participants With Solicited Adverse Events, Number of Participants With Unsolicited Adverse Events and 1 more. Started Jul 2019; status: completed.
02
Drugs
V184
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on NCT03807843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03807843.